<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">744409</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2021.744409</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>An Effective Treatment of Perimenopausal Syndrome by Combining Two Traditional Prescriptions of Chinese Botanical Drugs</article-title>
<alt-title alt-title-type="left-running-head">Lan et&#x20;al.</alt-title>
<alt-title alt-title-type="right-running-head">Traditional Chinese Medicine for PMS</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Lan</surname>
<given-names>Junjie</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wu</surname>
<given-names>Caiming</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liang</surname>
<given-names>Wen&#x2019;na</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shen</surname>
<given-names>Jianying</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhuo</surname>
<given-names>Zewei</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hu</surname>
<given-names>Liu</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ruan</surname>
<given-names>Luwei</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Pengheng</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ye</surname>
<given-names>Xiangrong</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xu</surname>
<given-names>Leqin</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Chengfu</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lin</surname>
<given-names>Shengyuan</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Chuanhui</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wu</surname>
<given-names>Siqi</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dong</surname>
<given-names>Yingjun</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1457780/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ren</surname>
<given-names>Haixia</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Huang</surname>
<given-names>Huiying</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gao</surname>
<given-names>Bizhen</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yao</surname>
<given-names>Hongwei</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lin</surname>
<given-names>Tianwei</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Chen</surname>
<given-names>Xueqin</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1392582/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Li</surname>
<given-names>Candong</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
</contrib>
</contrib-group>
<aff id="aff1">
<label>
<sup>1</sup>
</label>State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, State-Province Joint Engineering Laboratory of Targeted Drugs From Natural Products, School of Life Sciences, Xiamen University, Cancer Research Center of Xiamen University, <addr-line>Xiamen</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<label>
<sup>2</sup>
</label>Research Base of TCM syndrome, Fujian University of Traditional Chinese Medicine, <addr-line>Fuzhou</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<label>
<sup>3</sup>
</label>Xiamen Hospital of Traditional Chinese Medicine Affiliated to Fujian University of Traditional Chinese Medicine, <addr-line>Xiamen</addr-line>, <country>China</country>
</aff>
<aff id="aff4">
<label>
<sup>4</sup>
</label>First Hospital Affiliated to Fujian University of Medicine, <addr-line>Fuzhou</addr-line>, <country>China</country>
</aff>
<aff id="aff5">
<label>
<sup>5</sup>
</label>Institute of Molecular Enzymology, School of Biology and Basic Medical Sciences, Soochow University, <addr-line>Suzhou</addr-line>, <country>China</country>
</aff>
<aff id="aff6">
<label>
<sup>6</sup>
</label>The First Affiliated Hospital of Xiamen University, <addr-line>Xiamen</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1013663/overview">Shan-Yu Su</ext-link>, China Medical University, Taiwan</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/421367/overview">Lei Chen</ext-link>, Guangdong Ocean University, China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/445514/overview">Johanna Mahwahwatse Bapela</ext-link>, University of Pretoria, South Africa</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Candong Li, <email>fjzylcd@126.com</email>; Xueqin Chen, <email>xqchen@xmu.edu.cn</email>
</corresp>
<fn fn-type="equal" id="fn1">
<label>
<sup>&#x2020;</sup>
</label>
<p>These authors have contributed equally to this&#x20;work</p>
</fn>
<fn fn-type="other">
<p>This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>25</day>
<month>10</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>12</volume>
<elocation-id>744409</elocation-id>
<history>
<date date-type="received">
<day>20</day>
<month>07</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>20</day>
<month>09</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2021 Lan, Wu, Liang, Shen, Zhuo, Hu, Ruan, Zhang, Ye, Xu, Li, Lin, Yang, Wu, Dong, Ren, Huang, Gao, Yao, Lin, Chen and Li.</copyright-statement>
<copyright-year>2021</copyright-year>
<copyright-holder>Lan, Wu, Liang, Shen, Zhuo, Hu, Ruan, Zhang, Ye, Xu, Li, Lin, Yang, Wu, Dong, Ren, Huang, Gao, Yao, Lin, Chen and Li</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these&#x20;terms.</p>
</license>
</permissions>
<abstract>
<p>
<bold>Ethnopharmacological relevance:</bold> Two types of traditional Chinese formulas of botanical drugs are prescribed for treating perimenopausal syndrome (PMS), a disorder in middle-aged women during their transition to menopause. One is for treating PMS as kidney deficiency (KD) due to senescence and declining reproductive functions, and the other is for treating it as liver qi stagnation (LQS) in association with stress and anxiety. Despite the time-tested prescriptions, an objective attestation to the effectiveness of the traditional Chinese treatment of PMS is still to be established and the associated molecular mechanism is still to be investigated.</p>
<p>
<bold>Materials and methods:</bold> A model for PMS was generated from perimenopausal rats with chronic restraint stress (CRS). The effectiveness of traditional Chinese formulas of botanical drugs and a combination of two of the formulas was evaluated based on <sup>1</sup>H NMR plasma metabolomic, as well as behavioral and physiological, indicators. To investigate whether the formulas contained ligands that could compensate for the declining level of estrogen, the primary cause of PMS, the ligand-based NMR technique of saturation transfer difference (STD) was employed to detect possible interacting molecules to estrogen receptors in the decoction.</p>
<p>
<bold>Results:</bold> Each prescription of the classical Chinese formula moderately attenuated the metabolomic state of the disease model. The best treatment strategy however was to combine two traditional Chinese formulas, each for a different etiology, to adjust the metabolomic state of the disease model to that of rats at a much younger age. In addition, this attenuation of the metabolomics of the disease model was by neither upregulating the estrogen level nor supplementing an estrogenic compound.</p>
<p>
<bold>Conclusion:</bold> Treatment of PMS with a traditional Chinese formula of botanical drugs targeting one of the two causes separately could ameliorate the disorder moderately. However, the best outcome was to treat the two causes simultaneously with a decoction that combined ingredients from two traditional prescriptions. The data also implicated a new paradigm for phytotherapy of PMS as the prescribed decoctions contained no interacting compound to modulate the activity of estrogen receptors, in contrast to the treatment strategy of hormone replacement therapy.</p>
</abstract>
<kwd-group>
<kwd>perimenopausal syndrome</kwd>
<kwd>Chinese traditional medicine</kwd>
<kwd>phytotherapy</kwd>
<kwd>metabolomics</kwd>
<kwd>saturation transfer difference</kwd>
<kwd>ethnopharmacology</kwd>
</kwd-group>
<contract-num rid="cn001">81673882 81774209&#x20;31670729 31370724</contract-num>
<contract-sponsor id="cn001">National Natural Science Foundation of China<named-content content-type="fundref-id">10.13039/501100001809</named-content>
</contract-sponsor>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Perimenopause is a transition state in middle-aged women with gradually declining ovarian function and irregular menstrual cycles (<xref ref-type="bibr" rid="B42">Zhang et&#x20;al., 2013</xref>; <xref ref-type="bibr" rid="B12">Gemmell et&#x20;al., 2017</xref>; <xref ref-type="bibr" rid="B24">Marques-Lopes et&#x20;al., 2017</xref>; <xref ref-type="bibr" rid="B41">Zeng et&#x20;al., 2018</xref>). With erratically fluctuating and descending estrogen level in the body, approximately 40&#x2013;60% of perimenopausal women suffer from perimenopausal syndrome (PMS) characterized by disorders in the endocrine system and autonomic nervous system (<xref ref-type="bibr" rid="B16">Li et&#x20;al., 2013</xref>; <xref ref-type="bibr" rid="B39">Xu et&#x20;al., 2019</xref>). Clinical symptoms of PMS are diverse and include hot flashes, night sweats, insomnia, depression, irritability, fatigue, and cognitive impairment (<xref ref-type="bibr" rid="B32">Stearns et&#x20;al., 2002</xref>; <xref ref-type="bibr" rid="B10">Elkins et&#x20;al., 2008</xref>). The incidence of cardiovascular diseases, such as hypertension, atherosclerosis, myocardial infarction, and cerebral hemorrhage, increases in perimenopausal women with PMS (<xref ref-type="bibr" rid="B28">Nelson, 2008</xref>). The incidence of depression and osteoporosis is also higher in perimenopausal women with PMS than in healthy women (<xref ref-type="bibr" rid="B37">Whiteley et&#x20;al., 2013</xref>).</p>
<p>The diagnosis of traditional Chinese medicine (TCM) is based on symptom-based pattern differentiation (also known as symptom differentiation, Zheng differentiation, pattern diagnosis, and pattern classification) (<xref ref-type="bibr" rid="B21">Liang et&#x20;al., 2009</xref>; <xref ref-type="bibr" rid="B20">Liang et&#x20;al., 2011</xref>; <xref ref-type="bibr" rid="B18">Li et&#x20;al., 2015</xref>). Over the centuries of TCM practice, PMS is diagnosed as kidney deficiency (KD), a jargonistic term for the debility of bodily functions and loss of vitality, from senescence. Symptoms of insomnia, night sweat, lack of libido, back pain, and declining vitality, among others, were signs compatible with those of KD (<xref ref-type="bibr" rid="B21">Liang et&#x20;al., 2009</xref>; <xref ref-type="bibr" rid="B7">Chen et&#x20;al., 2020</xref>). However, KD does not seem to be the sole cause of PMS. As senescence is irreversible, aging could only deepen the degree of KD for middle-aged women. It is contradictory then that the symptoms of PMS will be naturally relieved in the later stage of perimenopause and after menopause as women get older. It is an indication that KD might not be the only cause for PMS. Obviously, other factors need to be taken into account in the diagnosis of PMS for better treatment.</p>
<p>The symptoms of hot flash, night sweat, insomnia, depression, irritability, fatigue, and cognitive impairment, which occur frequently in women suffering PMS, are compatible with those of liver qi stagnation (LQS), a diagnostic designation for illness correlated with anxiety and stress in pattern differentiation (<xref ref-type="bibr" rid="B22">Liang et&#x20;al., 2010</xref>; <xref ref-type="bibr" rid="B40">Yu et&#x20;al., 2018</xref>). There were demonstrations that prescriptions of decoctions for LQS were efficacious for treating PMS (<xref ref-type="bibr" rid="B22">Liang et&#x20;al., 2010</xref>; <xref ref-type="bibr" rid="B6">Chen et&#x20;al., 2014</xref>; <xref ref-type="bibr" rid="B17">Li et&#x20;al., 2014</xref>; <xref ref-type="bibr" rid="B18">Li et&#x20;al., 2015</xref>). For better prescription to treat PMS, it is important to investigate the physiological parameters for treating PMS as either KD, LQS, or a combination of&#x20;both.</p>
<p>Herein, a rat model for PMS was generated with aging and stress. <sup>1</sup>H NMR metabolomics of plasma samples showed that&#x20;a combined decoction for treating both KD and LQS could restore the metabolomic condition of the PMS rat model&#x20;to that of rats at a younger age before entering the perimenopausal period. The data also indicated that the treatment adopted here modulated the metabolic state of the PMS rat without either altering the serum level of estrogen or supplementing a constituent capable of interacting with an estrogen receptor to attenuate its activity, implicating that TCM treatment of PMS might be under a different paradigm from the typical treatment strategy of hormone replacement therapy which relieves the symptoms of PMS by supplementing an estrogenic compound to modulate the activity of estrogen receptors.</p>
</sec>
<sec sec-type="methods" id="s2">
<title>Methods</title>
<sec id="s2-1">
<title>Preparing the Decoctions</title>
<p>The botanical drugs used to prepare the decoctions were purchased from the Third People&#x2019;s Hospital of Fujian University of Traditional Chinese Medicine (FJUTCM). The botanical drugs were authenticated by the staff in the&#x20;Herb Identification, Teaching and Research Division of the College of Pharmacy of FJUTCM. The voucher specimens were kept in&#x20;the College of Pharmacy of FJUTCM, Fujian, China. The&#x20;decoctions, including those of Chaihu-Shugan-San (CSS),&#x20;Yougui, and Zuogui, were prepared according to the&#x20;Pharmacopoeia of the People&#x2019;s Republic of China (2015&#x20;Edition). The combined decoction of Zuogui and CSS (Zuogui-CSS) was also prepared. The ingredients are listed in <xref ref-type="table" rid="T1">Tables 1</xref>&#x2013;<xref ref-type="table" rid="T4">4</xref>.</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>The herbal composition of Chaihu-Shugan-San (CSS).</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Chinese name</th>
<th align="center">Botanical name (family name)</th>
<th align="center">Pharmaceutical name</th>
<th align="center">Amount (g)</th>
<th align="center">Voucher specimens</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">Chai Hu</td>
<td align="left">
<italic>Bupleurum chinense</italic> DC. (Apiaceae)</td>
<td align="left">Bupleuri radix</td>
<td align="char" char=".">6</td>
<td align="center">1000000618</td>
</tr>
<tr>
<td align="left">Bai Shao</td>
<td align="left">
<italic>Paeonia lactiflora</italic> Pall. (Paeoniaceae)</td>
<td align="left">Paeoniae radix alba</td>
<td align="char" char=".">4.5</td>
<td align="center">1000000608</td>
</tr>
<tr>
<td align="left">Zhi Ke</td>
<td align="left">
<italic>Citrus aurantium</italic> L. (Rutaceae)</td>
<td align="left">Aurantii fructus</td>
<td align="char" char=".">4.5</td>
<td align="center">1000000742</td>
</tr>
<tr>
<td align="left">Chuan Xiong</td>
<td align="left">
<italic>Ligusticum striatum</italic> DC. (Apiaceae)</td>
<td align="left">Chuanxiong rhizoma</td>
<td align="char" char=".">4.5</td>
<td align="center">1000000872</td>
</tr>
<tr>
<td align="left">Chen Pi</td>
<td align="left">
<italic>Citrus reticulata</italic> Blanco (Rutaceae)</td>
<td align="left">Citri reticulatae pericarpium</td>
<td align="char" char=".">6</td>
<td align="center">1000000674</td>
</tr>
<tr>
<td align="left">Xiang Fu</td>
<td align="left">
<italic>Cyperus rotundus</italic> L. (Cyperaceae)</td>
<td align="left">Cyperi rhizoma</td>
<td align="char" char=".">4.5</td>
<td align="center">1000001080</td>
</tr>
<tr>
<td align="left">Zhi Gan Cao</td>
<td align="left">
<italic>Glycyrrhiza uralensis</italic> Fisch. (Fabaceae)</td>
<td align="left">Glycyrrhizae radix et rhizoma praeparata cum melle</td>
<td align="char" char=".">1.5</td>
<td align="center">1000000884</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>The herbal composition of Yougui.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Chinese name</th>
<th align="center">Botanical name (family name)</th>
<th align="center">Pharmaceutical name</th>
<th align="center">Amount (g)</th>
<th align="center">Voucher specimens</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">Shu Di Huang</td>
<td align="left">
<italic>Rehmannia glutinosa</italic> (Gaertn.) DC. (Plantaginaceae)</td>
<td align="left">Rehmanniae radix praeparata</td>
<td align="center">9</td>
<td align="center">1000001065</td>
</tr>
<tr>
<td align="left">Shan Yao</td>
<td align="left">
<italic>Dioscorea oppositifolia</italic> L<italic>.</italic> (Dioscoreaceae)</td>
<td align="left">
<italic>Dioscorea</italic> rhizome</td>
<td align="center">9</td>
<td align="center">1000000908</td>
</tr>
<tr>
<td align="left">Shan Zhu Yu</td>
<td align="left">
<italic>Cornus officinalis</italic> Siebold &#x26; Zucc. (Cornaceae)</td>
<td align="left">Corni fructus</td>
<td align="center">6</td>
<td align="center">1000001097</td>
</tr>
<tr>
<td align="left">Gou Qi Zi</td>
<td align="left">
<italic>Lycium barbarum</italic> L<italic>.</italic> (Solanaceae)</td>
<td align="left">Lycii fructus</td>
<td align="center">9</td>
<td align="center">1000001087</td>
</tr>
<tr>
<td align="left">Zhi Gan Cao</td>
<td align="left">
<italic>Glycyrrhiza uralensis</italic> Fisch. (Fabaceae)</td>
<td align="left">Glycyrrhizae radix et rhizome</td>
<td align="center">3</td>
<td align="center">1000000884</td>
</tr>
<tr>
<td align="left">Du Zhong</td>
<td align="left">
<italic>Eucommia ulmoides</italic> Oliv<italic>.</italic> (Eucommiaceae)</td>
<td align="left">Eucommiae cortex</td>
<td align="center">9</td>
<td align="center">1000000792</td>
</tr>
<tr>
<td align="left">Rou Gui</td>
<td align="left">
<italic>Cinnamomum cassia</italic> (L.) J.Presl (Lauraceae)</td>
<td align="left">Cinnamomi cortex</td>
<td align="center">3</td>
<td align="center">1000001007</td>
</tr>
<tr>
<td align="left">Fu Zi</td>
<td align="left">
<italic>Aconitum carmichaeli</italic> Debeaux (Ranunculaceae)</td>
<td align="left">Aconiti lateralis radix praeparata</td>
<td align="center">6</td>
<td align="center">1000000606</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="T3" position="float">
<label>TABLE 3</label>
<caption>
<p>The herbal composition of Zuogui.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Chinese name</th>
<th align="center">Botanical name (family name)</th>
<th align="center">Pharmaceutical name</th>
<th align="center">Amount (g)</th>
<th align="center">Voucher specimens</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">Shu Di Huang</td>
<td align="left">
<italic>Rehmannia glutinosa</italic> (Gaertn.) DC. (Plantaginaceae)</td>
<td align="left">Rehmanniae radix praeparata</td>
<td align="center">9</td>
<td align="center">1000001065</td>
</tr>
<tr>
<td align="left">Shan Yao</td>
<td align="left">
<italic>Dioscorea oppositifolia</italic> L<italic>.</italic> (Dioscoreaceae)</td>
<td align="left">
<italic>Dioscorea</italic> rhizome</td>
<td align="center">6</td>
<td align="center">1000000908</td>
</tr>
<tr>
<td align="left">Shan Zhu Yu</td>
<td align="left">
<italic>Cornus officinalis</italic> Siebold &#x26; Zucc. (<italic>Cornace</italic>ae)</td>
<td align="left">Corni fructus</td>
<td align="center">6</td>
<td align="center">1000001097</td>
</tr>
<tr>
<td align="left">Gou Qi Zi</td>
<td align="left">
<italic>Lycium barbarum L.</italic> (Solanaceae)</td>
<td align="left">Lycii fructus</td>
<td align="center">6</td>
<td align="center">1000001087</td>
</tr>
<tr>
<td align="left">Zhi Gan Cao</td>
<td align="left">
<italic>Glycyrrhiza uralensis</italic> Fisch. (Fabaceae)</td>
<td align="left">Glycyrrhizae radix et rhizome praeparata cum melle</td>
<td align="center">3</td>
<td align="center">1000000884</td>
</tr>
<tr>
<td align="left">Fu Ling</td>
<td align="left">
<italic>Poria cocos</italic>
<xref ref-type="table-fn" rid="Tfn1">
<sup>a</sup>
</xref> (Polyporaceae)</td>
<td align="left">Poria</td>
<td align="center">4.5</td>
<td align="center">1000001020</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="Tfn1">
<label>a</label>
<p>
<italic>Poria cocos</italic> is the dried sclerotia of <italic>Wolfiporia cocos</italic> (F. A. Wolf) Ryvarden &#x26; Gilb.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="T4" position="float">
<label>TABLE 4</label>
<caption>
<p>The herbal composition of Zuogui-CSS.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Chinese name</th>
<th align="center">Botanical name (family name)</th>
<th align="center">Pharmaceutical name</th>
<th align="center">Amount (g)</th>
<th align="center">Voucher specimens</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">Chai Hu</td>
<td align="left">
<italic>Bupleurum chinense</italic> DC. (Apiaceae)</td>
<td align="left">Bupleuri radix</td>
<td align="center">6</td>
<td align="center">1000000618</td>
</tr>
<tr>
<td align="left">Bai Shao</td>
<td align="left">
<italic>Paeonia lactiflora</italic> Pall. (Paeoniaceae)</td>
<td align="left">Paeoniae radix alba</td>
<td align="center">4.5</td>
<td align="center">1000000608</td>
</tr>
<tr>
<td align="left">Zhi Ke</td>
<td align="left">
<italic>Citrus</italic> &#xd7; <italic>aurantium</italic> L. (Rutaceae)</td>
<td align="left">Aurantii fructus</td>
<td align="center">4.5</td>
<td align="center">1000000742</td>
</tr>
<tr>
<td align="left">Chuan Xiong</td>
<td align="left">
<italic>Ligusticum striatum</italic> DC (Apiaceae)</td>
<td align="left">Chuanxiong rhizoma</td>
<td align="center">4.5</td>
<td align="center">1000000872</td>
</tr>
<tr>
<td align="left">Chen Pi</td>
<td align="left">
<italic>Citrus reticulata</italic> Blanco (Rutaceae)</td>
<td align="left">Citri reticulatae pericarpium</td>
<td align="center">6</td>
<td align="center">1000000674</td>
</tr>
<tr>
<td align="left">Xiang Fu</td>
<td align="left">
<italic>Cyperus rotundus</italic> L. (Cyperaceae)</td>
<td align="left">Cyperi rhizoma</td>
<td align="center">4.5</td>
<td align="center">1000001080</td>
</tr>
<tr>
<td align="left">Zhi Gan Cao</td>
<td align="left">
<italic>Glycyrrhiza uralensis</italic> Fisch. (Fabaceae)</td>
<td align="left">Glycyrrhizae radix et Rhizoma praeparata cum melle</td>
<td align="center">4.5</td>
<td align="center">1000000884</td>
</tr>
<tr>
<td align="left">Shu Di Huang</td>
<td align="left">
<italic>Rehmannia glutinosa</italic> (Gaertn.) DC. (Plantaginaceae)</td>
<td align="left">Rehmanniae radix praeparata</td>
<td align="center">9</td>
<td align="center">1000001065</td>
</tr>
<tr>
<td align="left">Shan Yao</td>
<td align="left">
<italic>Dioscorea oppositifolia</italic> L<italic>.</italic> (Dioscoreaceae)</td>
<td align="left">
<italic>Dioscorea</italic> rhizoma</td>
<td align="center">6</td>
<td align="center">1000000908</td>
</tr>
<tr>
<td align="left">Shan Zhu Yu</td>
<td align="left">
<italic>Cornus officinalis</italic> Siebold &#x26; Zucc. (Cornaceae)</td>
<td align="left">Corni fructus</td>
<td align="center">6</td>
<td align="center">1000001097</td>
</tr>
<tr>
<td align="left">Gou Qi Zi</td>
<td align="left">
<italic>Lycium barbarum</italic> L<italic>.</italic> (Solanaceae)</td>
<td align="left">Lycii fructus</td>
<td align="center">6</td>
<td align="center">1000001087</td>
</tr>
<tr>
<td align="left">Fu Ling</td>
<td align="left">
<italic>Poria cocos</italic>
<xref ref-type="table-fn" rid="Tfn2">
<sup>a</sup>
</xref> (Polyporaceae)</td>
<td align="left">Poria</td>
<td align="center">4.5</td>
<td align="center">1000001020</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="Tfn2">
<label>a</label>
<p>
<italic>Poria cocos</italic> is the dried sclerotia of <italic>Wolfiporia cocos</italic> (F. A. Wolf) Ryvarden &#x26; Gilb.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>For preparing the decoctions, botanical drugs for each formula were mixed and macerated in distilled water at room temperature for 1&#xa0;h. The mixture was then decocted twice with distilled water for half of an hour, at a ratio of 1:10 w/v and at a ratio of 1:5 w/v, respectively. The two resultant decoctions were combined, centrifuged, and filtrated. The decoctions of CSS, Yougui, Zuogui, and Zuogui-CSS were concentrated to 0.2777, 0.476, 0.304, and 0.5817&#xa0;g/ml of the crude drugs, respectively. All decoctions were stored at &#x2212;80&#xb0;C.</p>
</sec>
<sec id="s2-2">
<title>Generation of the Rat Model for PMS With KD and LQS</title>
<p>SPF-grade (specific pathogen-free grade) female Sprague-Dawley (SD) rats (5&#xa0;months old) were purchased from Shanghai Xipuer-Bikai Laboratory Animal Co., Ltd. (Shanghai, China). Animals were housed in individually ventilated cages and kept in an environmentally controlled room with a 12&#xa0;h light/dark cycle at constant temperature (23&#xb0;C) and humidity (55%). The rats had free access to the standard laboratory water and&#x20;diet.</p>
<p>Perimenopausal rats were generated based on previous studies (<xref ref-type="bibr" rid="B2">Cai et&#x20;al., 2016</xref>; <xref ref-type="bibr" rid="B7">Chen et&#x20;al., 2020</xref>). These rats were with irregular menstrual cycles at the age of about 11&#x2013;13&#xa0;months. Forty of these perimenopausal rats were selected and randomly divided into five groups with eight rats each. The rat model with KD and LQS was generated by the method of chronic restraint stress (CRS) (<xref ref-type="bibr" rid="B19">Liang et&#x20;al., 2015</xref>). The food intake, water intake, body weight, appearance, and activity of the rats were monitored weekly throughout the experiment. Plasma concentrations of estrogen (E2), adrenocorticotropic hormone (ACTH), cortisol (CORT), corticotropin-releasing hormone (CRH), 5-hydroxytryptamine (5-HT), dopamine (DA), and beta-endorphin (&#x3b2;-EP) were determined by ELISA (with kits from CUSABIO, China).</p>
<p>The human equivalent dose (HED) for rat has a multiplication factor of 6:37 (<xref ref-type="bibr" rid="B30">Reagan-Shaw et&#x20;al., 2008</xref>). So the final concentration of crude drugs for Yougui, Zuogui, CSS, and Zuogui-CSS was adjusted to 0.476, 0.304, 0.2777, and 0.5817&#xa0;g/ml, respectively. The decoctions were administered by gavage with a feeding tube once daily for 4&#xa0;weeks at a dose of 1&#xa0;ml for every 100&#xa0;g of body weight. After overnight fasting, blood samples were collected and centrifuged. All plasma samples were stored at &#x2212;80&#xb0;C.</p>
</sec>
<sec id="s2-3">
<title>Sample Preparations and <sup>1</sup>H NMR Data Acquisition</title>
<p>The NMR spectra were acquired at 298&#xa0;K on a 600&#xa0;MHz Bruker AVANCE II NMR spectrometer (Bruker BioSpin, Rheinstetten, Germany) operating at 600.13&#xa0;MHz for <sup>1</sup>H signals. The <sup>1</sup>H NMR spectrum was acquired using a Carr-Purcell-Meiboom-Gill (CPMG, RD-90-(&#x3c4;cp-180-&#x3c4;cp)-acquisition) spin-echo pulse sequence to suppress the water with a total spin-spin relaxation delay (RD) of 320&#xa0;ms to attenuate broad signals from proteins and lipoproteins due to their short transverse relaxation time. Each <sup>1</sup>H NMR spectrum was obtained with 80 scans with a spectral width of 12335.5&#xa0;Hz, spectral size of 65,536 points, pulse width (PW) of 30&#xb0; (12.7&#xa0;&#x3bc;s), and RD of 2.0&#xa0;s. The FIDs were Fourier transformed with LB &#x3d; 0.3&#xa0;Hz.</p>
<p>The <sup>1</sup>H NMR spectra were manually corrected for phase and baseline with the Topspin 3.2 software. Integrations of water resonance (4.70&#x2013;5.15&#xa0;ppm) in the spectra of aqueous samples were excluded. The metabolites were normalized to the total integrated spectral area (&#x2212;0.55&#x2013;8.55&#xa0;ppm) for aqueous samples. The data sets were log-transformed and Pareto-scaled (mean-centered and divided by the square root of the standard deviation of each variable) prior to statistical analysis.</p>
</sec>
<sec id="s2-4">
<title>Multivariate Analysis</title>
<p>Multivariate analyses of the NMR spectra were carried out with the algorithm of PLS-DA (Partial Least Square Discriminant Analysis) implemented in MetaboAnalyst 4.0 (<xref ref-type="bibr" rid="B8">Chong et&#x20;al., 2018</xref>). The model quality was validated based on two parameters, R<sup>2</sup> (goodness-of-fit parameter) and Q<sup>2</sup> (predictive ability). A model with a large <italic>R</italic>
<sup>2</sup> (close to 1) and Q<sup>2</sup> (Q<sup>2</sup> &#x2265; 0.5) was considered an excellent model. The PLS-DA model was also validated by the permutation test in which the class membership was randomly shuffled by 100&#x20;times for calculating the response values. The new <italic>R</italic>
<sup>2</sup> and Q<sup>2</sup> values were lower than the original ones indicating that the model was not overfitting (<xref ref-type="bibr" rid="B4">Chang et&#x20;al., 2007</xref>).</p>
<p>The important metabolites were identified based on their respective variable influence on projection (VIP) score in the PLS-DA analysis. Significant differences of the selected signals of the main metabolites, which were responsible for class discrimination, were analyzed using a <italic>t</italic>-test in GraphPad Prism 5 software. The data are presented as <italic>p &#x3c;</italic> 0.05 (&#x2a;), <italic>p &#x3c;</italic> 0.01 (&#x2a;&#x2a;), and <italic>p &#x3c;</italic> 0.001 (&#x2a;&#x2a;&#x2a;).</p>
</sec>
<sec id="s2-5">
<title>Protein Production and Saturation Transfer Difference (STD) NMR Experiment</title>
<p>The human ligand-binding domain of estrogen receptor &#x3b1; (ER&#x3b1; LBD) containing residues 297&#x2013;554 in the ER&#x3b1; sequence was expressed in <italic>E.coli</italic> with BL21 (DE) cells and a pET-22b vector. It was purified following an established protocol (<xref ref-type="bibr" rid="B1">Bruning et&#x20;al., 2010</xref>). STD NMR (<xref ref-type="bibr" rid="B25">Mayer and Meyer, 2001</xref>; <xref ref-type="bibr" rid="B26">Meyer and Peters, 2003</xref>) was employed to detect the ER&#x3b1; LBD interaction with small molecules in the TCM decoctions at 298&#xa0;K on an 850&#xa0;MHz Bruker ADVANCE III spectrometer (Bruker BioSpin, Rheinstetten, Germany) equipped with a TCI CryoProbe. The RD was set to 2&#xa0;s. Selective on-resonance irradiation frequency was set to 0.47&#xa0;ppm with a saturation time of 2&#xa0;s. The selective saturation was achieved by a train of 50&#xa0;ms Gauss-shaped pulses separated by a 2&#xa0;ms delay. The duration of the presaturation of 2&#xa0;s was adjusted using <italic>n</italic>&#x20;&#x3d; 128 cycles. Off-resonance irradiation frequency for the reference spectrum was applied at 50&#xa0;ppm. The decoction of Zuogui-CSS was mixed with the recombinant ER&#x3b1; LBD (20&#xa0;&#x3bc;M) in phosphate buffer (50&#xa0;mM sodium phosphate, pH 7.4, 150&#xa0;mM NaCl, and 5% glycerol) in the presence of 10% D<sub>2</sub>O (Cambridge Isotope Laboratories, United&#x20;States). The NMR data were analyzed with the Topspin 3.2 software.</p>
</sec>
<sec id="s2-6">
<title>
<italic>In Vitro</italic> Gastrointestinal Digestion</title>
<p>Simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) were prepared following the protocols in Pharmacopoeia of the People&#x2019;s Republic of China (2015 Edition). SGF was prepared by mixing 16.40&#xa0;ml of diluted hydrochloric acid, 800&#xa0;ml of Milli-Q water, and 10&#xa0;g of pepsin (Sigma-Aldrich, P7012) to a final volume of 1,000&#xa0;ml. SGF thus prepared had a pH value of about 1.4. Solution A for SIF was prepared by dissolving 6.80&#xa0;g of potassium dihydrogen phosphate in Milli-Q water to a final volume of 500&#xa0;ml. The pH value of solution A was adjusted to 6.8 with a NaOH solution (0.1&#xa0;mol/L). Solution B for SIF was prepared by dissolving 10&#xa0;g of pancreatin (Sigma-Aldrich, P7545) in Milli-Q water. Solutions A and B were mixed and the final volume was adjusted to 1,000&#xa0;ml with Milli-Q water to make&#x20;SIF.</p>
<p>The SGF-treated Zuogui-CSS was prepared by incubating Zuogui-CSS with SGF at a ratio of 1:10 at 37&#xb0;C with shaking at 100&#xa0;rpm for 2&#xa0;h. The sample was then dried using a rotary evaporator at 70&#xb0;C. The SGF-treated samples were rehydrated with Milli-Q water. Similarly, Zuogui-CSS was treated with SIF by mixing Zuogui-CSS and SIF in a ratio of 1:4 for a 4&#xa0;h incubation. It was similarly dried and then rehydrated as for the SGF-treated samples. Zuogui-CSS was also sequentially treated with SGF for 2&#xa0;h and SIF for 4&#xa0;h. The SGF- and SIF-treated samples were analyzed by <sup>1</sup>H NMR spectroscopy.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<sec id="s3-1">
<title>Perimenopause Was Accompanied by Metabolomic Changes</title>
<p>The perimenopausal rats (PM rats) were with irregular menstrual cycles starting at the age of about 12&#x20;months old and these rats were deemed to be with KD (<xref ref-type="bibr" rid="B27">Miao et&#x20;al., 2018</xref>; <xref ref-type="bibr" rid="B7">Chen et&#x20;al., 2020</xref>). The weight, sugar preference rate, and behavior indices of rats were of no significant difference between 6-month-old rats and perimenopausal rats, based on sugar preference test (SPT) and open-field test (OFT) (<xref ref-type="bibr" rid="B33">Strekalova et&#x20;al., 2004</xref>; <xref ref-type="bibr" rid="B15">Kraeuter et&#x20;al., 2019</xref>) (<xref ref-type="sec" rid="s11">Supplementary Figure S1</xref>). While the levels of CRH, CORT, &#x3b2;-EP, and 5-HT showed no significant difference, the levels of E2 and DA were lower in perimenopausal rats, whereas the level of ACTH was upregulated (<xref ref-type="sec" rid="s11">Supplementary Figure S2</xref>). These data were compatible with the physiological state of the perimenopausal rats (<xref ref-type="bibr" rid="B3">Cai et&#x20;al., 2007</xref>; <xref ref-type="bibr" rid="B11">Fu et&#x20;al., 2017</xref>).</p>
<p>In the preceding study, the metabolic profiles of rats entering the perimenopausal state and that of younger age were clearly different with metabolites for energy metabolism, such as lipid, glucose, trimethylamine-n-oxide, glutamine, pyruvate, acetoacetate, citrate, betaine, and acetone, influencing the shift of metabolomes (<xref ref-type="bibr" rid="B7">Chen et&#x20;al., 2020</xref>).</p>
</sec>
<sec id="s3-2">
<title>Influence of LQS on Perimenopausal Rats</title>
<p>To generate a rat model for PMS, the perimenopausal rats were treated with CRS. These rats were considered to be with both KD and LQS (<xref ref-type="bibr" rid="B18">Li et&#x20;al., 2015</xref>; <xref ref-type="bibr" rid="B27">Miao et&#x20;al., 2018</xref>). The PMS rats were with a weight loss (<xref ref-type="fig" rid="F1">Figure&#x20;1A</xref>), decreased sugar preference rate (<xref ref-type="fig" rid="F1">Figure&#x20;1B</xref>), and reduced level of activity compared to either the 6-month-old or the PM rats without the stress (<xref ref-type="sec" rid="s11">Supplementary Figure S3</xref>). The analyses also showed that the concentrations of E2, DA, &#x3b2;-EP, and 5-HT in the peripheral blood of the PMS rats decreased rapidly (<xref ref-type="fig" rid="F1">Figures 1C&#x2013;E</xref>), while the levels of ACTH and CORT in direct correlation with the HPA axis reactivity were elevated. These data indicated that PMS rats were under stress and depression.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>PMS rats. <bold>(A)</bold> The body weights of 6-month-old, PM, and PMS rats. The PMS rats were with significant weight loss. <bold>(B)</bold> The PMS rats were of decreased sugar preference rate. <bold>(C)</bold> The level of estrogen in PMS rats was further decreased from that of perimenopausal rats. <bold>(D)</bold> The levels of ACTH and CORT in PMS rats were enhanced, while the level of CRH was not significantly altered. <bold>(E)</bold> The levels of &#x3b2;-EP, 5-HT, and DA were all lowered in PMS rats. &#x201c;&#x2a;&#x201d; indicates the comparison with the 6-month-old rats [<italic>p</italic>&#x20;&#x3c; 0.05 (&#x2a;)]; &#x201c;&#x25b3;&#x201d; indicates the comparison with the perimenopausal rats [<italic>p</italic>&#x20;&#x3c; 0.05 (&#x25b3;)].</p>
</caption>
<graphic xlink:href="fphar-12-744409-g001.tif"/>
</fig>
<p>The metabolomic states between PM rats and PMS rats were distinctly different (<xref ref-type="fig" rid="F2">Figure&#x20;2A</xref>) and the metabolites that dictated the metabolomic change in the PMS rats were glucose and lipid (<xref ref-type="sec" rid="s11">Supplementary Figure S4</xref> and <xref ref-type="fig" rid="F2">Figure&#x20;2B</xref>). The levels of creatine, glycerol, trimethylamine-n-oxide, betaine, glutamine, pyruvate, acetoacetate, methionine, and glycoproteins increased in the plasma of PMS rats. In addition, the concentrations for unsaturated lipid, glycine, acetone, acetate, and isoleucine decreased (<xref ref-type="sec" rid="s11">Supplementary Figure S5</xref> and <xref ref-type="sec" rid="s11">Supplementary Table&#x20;S1</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Metabolomic profiles of 6-month-old, PM and PMS rats. <bold>(A)</bold> 3D representation of PLS-DA analysis of the PM (green) and PMS rats (red). The metabolomic profiles of the PMS rats changed significantly. <bold>(B)</bold> Transition from perimenopause to PMS, the levels of glucose were upregulated, while the levels of lipid were downregulated. <bold>(C)</bold> PLS-DA analysis of metabolomic profile from the plasma of 6-month-old rats (green) and PMS rats (red). <bold>(D)</bold> Compared with 6-month-old rats, the levels of glucose and lipid were upregulated. <italic>p</italic>&#x20;&#x3c; 0.01 (&#x2a;&#x2a;).</p>
</caption>
<graphic xlink:href="fphar-12-744409-g002.tif"/>
</fig>
<p>The metabolomic profile of PMS rats was also distinct from that of the 6-month-old rats (<xref ref-type="fig" rid="F2">Figure&#x20;2C</xref>) with elevated levels of glucose, creatine, trimethylamine N-oxide, betaine, choline, creatinine, citrate, glutamine, succinate, pyruvate, acetoacetate, methionine, glycoprotein, acetate, and valine, but a downregulated level of glycine (<xref ref-type="fig" rid="F2">Figure&#x20;2D</xref>, <xref ref-type="sec" rid="s11">Supplementary Figures S6, S7</xref>, and <xref ref-type="sec" rid="s11">Supplementary Table&#x20;S2</xref>).</p>
<p>The above data indicated that the glucose metabolism and lipid metabolism of perimenopausal rats were upregulated from those of the 6-month-old rat. Entering the LQS state, the glucose metabolism was upregulated but the lipid metabolism was suppressed in PMS rats comparing to the perimenopausal rats. This aberrant state of glucose metabolism was in line with the fact that the rats were under stress and LQS was associated with downregulated lipid metabolism.</p>
</sec>
<sec id="s3-3">
<title>Influence of the Decoctions for KD on PMS Rats</title>
<p>After entering the PMS state, the metabolomic state changed rapidly without any treatment (<xref ref-type="fig" rid="F3">Figure&#x20;3A</xref>). Since PMS would be with both KD and LQS by TCM diagnosis, it would be reasonable to treat the model with the corresponding prescriptions in TCM. KD was subdivided into kidney yin deficiency, kidney yang deficiency, and the combination of the two. Traditionally, Yougui, a decoction made from a mix of Chinese botanical drugs (<xref ref-type="table" rid="T2">Table&#x20;2</xref>), is prescribed for kidney yang deficiency and Zuogui (<xref ref-type="table" rid="T3">Table&#x20;3</xref>) is prescribed for kidney yin deficiency (<xref ref-type="bibr" rid="B43">Zhao et&#x20;al., 2011</xref>; <xref ref-type="bibr" rid="B13">He et&#x20;al., 2014</xref>; <xref ref-type="bibr" rid="B11">Fu et&#x20;al., 2017</xref>; <xref ref-type="bibr" rid="B5">Chen et&#x20;al., 2019</xref>). Previously, we discovered that both decoctions of Zuogui and Yougui could adjust the metabolomic states of PM rats (<xref ref-type="bibr" rid="B7">Chen et&#x20;al., 2020</xref>). Metabolomic regulations of PMS rats by these two decoctions were also investigated.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Treatment with Yougui. <bold>(A)</bold> The metabolomics state of PMS (red) further progressed away from the original state after 4&#xa0;weeks of gavage with a saline solution (green). The metabolic state changed rapidly. <bold>(B)</bold> Weight changes of PMS rats treated with Yougui. There was no statistically significant difference in the weight of PMS rats before and after treatment with Yougui. <bold>(C)</bold> Treatment of Yougui did not result in a statistically different E2 level in PMS rats. <bold>(D)</bold> ELISA results of ACTH, CORT, and CRH. Compared with PMS rats, the levels of ACTH and CORT were reduced after treatment with Yougui. <bold>(E)</bold> The levels of DA, &#x3b2;-EP, and 5-HT. Compared with PMS rats, the levels of DA were enhanced after treatment with Yougui. &#x201c;&#x2a;&#x201d; indicates the comparison with 6-month-old rats [<italic>p</italic>&#x20;&#x3c; 0.05 (&#x2a;)]; &#x201c;&#x25b3;&#x201d; indicates the comparison with the perimenopausal rats [<italic>p</italic>&#x20;&#x3c; 0.05 (&#x25b3;)]; &#x201c;&#x23;&#x201d; indicates the comparison with the PMS rats [<italic>p</italic>&#x20;&#x3c; 0.05 (&#x23;)].</p>
</caption>
<graphic xlink:href="fphar-12-744409-g003.tif"/>
</fig>
<p>PMS rats were treated with the decoction of Yougui (Yougui) for comparison with rats of 6-months old and of perimenopause. The treatment of Yougui showed little influence on the weight (<xref ref-type="fig" rid="F3">Figure&#x20;3B</xref>) and the level of E2 of PMS rats (<xref ref-type="fig" rid="F3">Figure&#x20;3C</xref>). However, the levels of ACTH and CORT were reduced, while the level of DA increased (<xref ref-type="fig" rid="F3">Figures 3D,E</xref>). Overall, following the treatment with Yougui, the weight and the abovementioned endocrine indexes of PMS rats were not significantly changed. The E2 level was not significantly different either (<xref ref-type="fig" rid="F3">Figure&#x20;3</xref>).</p>
<p>Yougui treatment did alter the metabolomic state of PMS rats by bringing the metabolomic state of PMS rats closer to that of perimenopausal rats (<xref ref-type="fig" rid="F4">Figures 4A,B</xref>). The metabolomic difference between PMS rats treated with Yougui and rats of 6&#x20;months old though was still significant (<xref ref-type="fig" rid="F4">Figure&#x20;4C</xref>). Overall, the data indicated that Yougui treatment improved the metabolomic state of PMS rats and brought its metabolomic profile closer to those of perimenopausal rats without LQS (<xref ref-type="fig" rid="F4">Figure&#x20;4D</xref>). The dominant metabolites altering the metabolomic profile in the Yougui treatment were lipid, glucose, amino acids, and proteins (<xref ref-type="sec" rid="s11">Supplementary Figures S8&#x2013;S10</xref>).</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Yougui regulated the metabolomic state of PMS rats. <bold>(A)</bold> PLS-DA analysis of metabolomic profile from the plasma of PMS rats before (red) and after (green) treatment with Yougui. <bold>(B)</bold> Metabolomic profile of the plasma of Yougui-treated PMS rats (green) and perimenopausal rats (red). <bold>(C)</bold> Metabolomic profile from the plasma of Yougui-treated PMS rats (green) and that of 6-month-old rats (red). <bold>(D)</bold> PLS-DA analysis of metabolomics profiles from the plasmas of PMS rats treated with (blue) and without Yougui (purple), perimenopausal (green) rats, and 6-month-old rats (red). Yougui treatment modulated the metabolomic state of PMS rats towards that of rats at younger&#x20;ages.</p>
</caption>
<graphic xlink:href="fphar-12-744409-g004.tif"/>
</fig>
<p>After Yougui treatment, the levels of acetate and isoleucine increased significantly in the PMS rats, but the level of glucose decreased. In comparison to the 6-month-old rats, the levels of creatine, trimethylamine-n-oxide, choline, creatinine, glutamine, acetoacetate, glycoprotein, acetate, valine, isoleucine, and leucine were significantly higher (<xref ref-type="sec" rid="s11">Supplementary Figure S11</xref> and <xref ref-type="sec" rid="s11">Supplementary Table&#x20;S3</xref>).</p>
<p>While Yougui is generally prescribed for kidney yang deficiency, the decoction of Zuogui (Zuogui) (<xref ref-type="table" rid="T3">Table&#x20;3</xref>) is for kidney yin deficiency in centuries of TCM practice (<xref ref-type="bibr" rid="B13">He et&#x20;al., 2014</xref>). Treatment of PMS rats with Zuogui showed minimal influence on the body weight (<xref ref-type="sec" rid="s11">Supplementary Figure S12</xref>). Similar to the treatment with Yougui, treatment with Zuogui did not lead to a significant change in the level of E2 in PMS rats (<xref ref-type="fig" rid="F5">Figure&#x20;5A</xref>), but the levels of CORT and ACTH were reduced, and the level of DA was increased. Unlike Yougui, Zuogui treatment increased the level of &#x3b2;-EP (<xref ref-type="fig" rid="F5">Figures&#x20;5B,C</xref>).</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>Zuogui regulated the levels of metabolites and endocrine indexes in PMS rats. <bold>(A)</bold> The E2 levels of PMS rats treated Zuogui were not significantly different. <bold>(B)</bold> The levels of ACTH and CORT of PMS rats were reduced after the treatment with Zuogui. <bold>(C)</bold> The levels of DA and &#x3b2;-EP in PMS rats were enhanced after being treated with Zuogui. <bold>(D)</bold> PLS-DA analysis of metabolomics profiles for PMS rats treated with (green) and without Zuogui (red). <bold>(E)</bold> Metabolomic profiles of PMS rats (purple), PMS rats treated with Zuogui (blue), perimenopausal rats (green), and 6-month-old rats (red). &#x201c;&#x2a;&#x201d; indicates the comparison with 6-month-old rats [<italic>p</italic>&#x20;&#x3c; 0.05 (&#x2a;)]; &#x201c;&#x25b3;&#x201d; indicates the comparison with perimenopausal rats [<italic>p</italic>&#x20;&#x3c; 0.05 (&#x25b3;)]; &#x201c;&#x23;&#x201d; indicates the comparison with PMS rats [<italic>p</italic>&#x20;&#x3c; 0.05 (&#x23;)].</p>
</caption>
<graphic xlink:href="fphar-12-744409-g005.tif"/>
</fig>
<p>Zuogui modulated the metabolomic state of the PMS rats (<xref ref-type="fig" rid="F5">Figure&#x20;5D</xref>). Lipid, glucose, proteins, and trimethylamine-n-oxide were important metabolites influencing the metabolomic profile (<xref ref-type="sec" rid="s11">Supplementary Figure S13</xref>). Although the metabolomic profile moved in the direction of the perimenopausal rats, the adjustment was not sufficient to bring the metabolomic state of PMS rats to that of 6-months old (<xref ref-type="fig" rid="F5">Figure&#x20;5E</xref>).</p>
<p>Zuogui upregulated the levels of unsaturated lipid, glutamine, acetate, valine, and lipid while downregulated the levels of creatine, trimethylamine-n-oxide, creatinine, glutamine, pyruvate, acetoacetate, and glycoproteins in the PMS rats. Notably, after the Zuogui treatment, the levels of creatine, creatinine, glutamine, pyruvate, glycoproteins, and citrate were brought to the metabolic levels of the 6-month-old rats (<xref ref-type="sec" rid="s11">Supplementary Figure S14</xref> and <xref ref-type="sec" rid="s11">Supplementary Table S4</xref>). It seemed that Zuogui attenuated the metabolism of PMS rats effectively, but it might also indicate that the PMS rats used here were more of kidney yin deficiency than kidney yang deficiency.</p>
</sec>
<sec id="s3-4">
<title>Influence of CSS on the PMS Rats</title>
<p>CSS (<xref ref-type="table" rid="T1">Table&#x20;1</xref>) is a classical prescription of TCM to treat LQS-associated illness. CSS was documented as early as 1624 in a book of TCM, Jing Yue Quan Shu. The decoction is an effective prescription for ameliorating depression and anxiety (<xref ref-type="bibr" rid="B35">Su et&#x20;al., 2011</xref>; <xref ref-type="bibr" rid="B34">Su et&#x20;al., 2014</xref>).</p>
<p>As shown in <xref ref-type="sec" rid="s11">Supplementary Figure S15</xref>, not much change was observed in the weight of PMS rats treated with CSS as compared to that of the 6-month-old or perimenopausal rats. The changes in the levels of E2 and CORT were not significant either (<xref ref-type="fig" rid="F6">Figures 6A,B</xref>). There was a significant reduction in the level of ACTH however and a considerable increase in the levels of &#x3b2;-EP, 5-HT, and DA in PMS rats treated with CSS, suggesting that CSS altered the endocrine parameters of PMS rats in the favorable direction (<xref ref-type="fig" rid="F6">Figure&#x20;6C</xref>).</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>PMS rats treated with CSS. <bold>(A)</bold> The E2 level of the PMS rats with treatment was not significantly different. <bold>(B)</bold> Compared with the PMS rats, the levels of ACTH were reduced after treatment with CSS. <bold>(C)</bold>. The levels of &#x3b2;-EP, 5-HT, and DA in PMS rats were enhanced after the treatment with CSS. <bold>(D)</bold> Metabolomic profiles of PMS rats with (red) and without (green) the CSS treatment. <bold>(E)</bold> PLS-DA analysis of the metabolomics of plasma from that CSS-treated PMS (blue), PMS (purple), perimenopausal (green), and 6-month-old (red) rats. &#x201c;&#x2a;&#x201d; indicates the comparison with 6-month-old rats [<italic>p</italic>&#x20;&#x3c; 0.05 (&#x2a;)]; &#x201c;&#x25b3;&#x201d; indicates the comparison with perimenopausal rats [<italic>p</italic>&#x20;&#x3c; 0.05 (&#x25b3;)]; &#x201c;&#x23;&#x201d; indicates the comparison with untreated PMS rats [<italic>p</italic>&#x20;&#x3c; 0.05 (&#x23;)].</p>
</caption>
<graphic xlink:href="fphar-12-744409-g006.tif"/>
</fig>
<p>CSS treatment effectively modulated the metabolomic profile of PMS rats (<xref ref-type="fig" rid="F6">Figure&#x20;6D</xref>). It brought the metabolomic state of the PMS rats closer to that of the PM rats but still not to that of the 6&#xa0;months old (<xref ref-type="fig" rid="F6">Figure&#x20;6E</xref>). It upregulated the levels of the unsaturated lipids, isoleucine, and&#x20;lipid while downregulating the levels of glucose, creatine, betaine, creatinine, glutamine, pyruvate, and acetoacetate. The dominant metabolites for changing the metabolomic state by CSS were glucose and lipid (<xref ref-type="sec" rid="s11">Supplementary Figure S16</xref>). In comparison with the 6-month-old rats, the levels of most of the metabolites were higher, including trimethylamine-n-oxide, betaine, choline, citrate, glutamine, acetoacetate, acetone, methionine, glycoprotein, acetate, valine, isoleucine, leucine, and lipid. Moreover, the levels of glucose, creatine, pyruvate, glycerol, creatinine, and succinate were adjusted to that of the 6&#xa0;months old <xref ref-type="sec" rid="s11">Supplementary Figure S17</xref>, <xref ref-type="sec" rid="s11">Supplementary Table S5</xref>). Overall, CSS upregulated the metabolism of lipid and downregulated the metabolism of glucose. Considering that LQS rats were with upregulated glucose metabolism and downregulated lipid metabolism, the data is consistent with the fact that CSS is with a tranquilizing potency.</p>
</sec>
<sec id="s3-5">
<title>A Combination Treatment for PMS</title>
<p>The aforementioned data indicated that both glucose and lipid metabolisms were upregulated in perimenopausal rats. In LQS rats, however, the glucose metabolism was further upregulated, while the lipid metabolism was downregulated. It was previously shown that the&#x20;glucose and lipid metabolisms were both upregulated for the perimenopausal rats by the treatment with either Yougui or Zuogui (<xref ref-type="bibr" rid="B7">Chen et&#x20;al., 2020</xref>). For the PMS rats though the glucose metabolism was downregulated, the lipid metabolism was upregulated for PMS rats treated with either Yougui, Zuogui, or CSS. It seemed that each of these decoctions was of various degrees of benefits in treating PMS rats based on the metabolomic indicators. However, none of these decoctions was effective enough to bring the metabolomic state of PMS rats to that of rats before entering the perimenopause.</p>
<p>As different decoctions for KD and LQS seem to adjust the metabolomics in different directions and attenuate different sets of metabolites, one would naturally wonder what would be the effect if both KD and LQS were ameliorated simultaneously. To this end, a decoction containing ingredients from Zuogui-CSS was prepared for the gavage of PMS&#x20;rats.</p>
<p>The weight of PMS rats was not dramatically changed by the treatment with this decoction containing ingredients from Zuogui-CSS (<xref ref-type="sec" rid="s11">Supplementary Figure S18A</xref>). The level of E2 was not significantly altered with the treatment either (<xref ref-type="sec" rid="s11">Supplementary Figure S18B</xref>). The ACTH and CORT levels of peripheral blood dropped after the treatment, but the levels of DA, &#x3b2;-EP, and 5-HT increased (<xref ref-type="sec" rid="s11">Supplementary Figures S18C,D</xref>).</p>
<p>The metabolomic analysis indicated that the combined treatment of Zuogui-CSS was effective for restoring a metabolic state of PMS (<xref ref-type="fig" rid="F7">Figure&#x20;7</xref>). Treatment with Zuogui-CSS not only adjusted the metabolomic state of the PMS rats to that of the perimenopausal rats but also brought the metabolomic profile of PMS rats to the proximity of the metabolomic profile of the 6-month-old rats (<xref ref-type="fig" rid="F7">Figure&#x20;7B</xref>). Further analysis indicated that Zuogui-CSS modulation of the metabolome of PMS rats was with lipid and glucose as the dominant factors (<xref ref-type="sec" rid="s11">Supplementary Figure S19</xref>). The Zuogui-CSS treatment significantly lowered the levels of glucose, glycerol, trimethylamine-n-oxide, betaine, glutamine, acetoacetate, methionine, glycoprotein, valine, and leucine, but the levels were still higher than those of the 6-month-old rats. In contrast, the pyruvate concentration in PMS rats was even lower than that in the 6-month-old rats after the treatment. Other metabolites, such as creatine, citrate, succinate, acetoacetate, acetone, glycine, and isoleucine, were of similar levels between PMS rats treated with Zuogui-CSS and the 6-month-old rats (<xref ref-type="sec" rid="s11">Supplementary Figure S20</xref>; <xref ref-type="sec" rid="s11">Supplementary Table&#x20;S6</xref>).</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>A combination treatment for PMS. <bold>(A)</bold> PLS-DA analysis of metabolomics for the plasmas of PMS rats treated with (red) and without Zuogui-CSS (green). <bold>(B)</bold> Metabolomic profiles of the plasmas of PMS rats treated with Zuogui-CSS (blue), PMS rats (purple), perimenopausal rats (green), and rats of 6&#xa0;months old (red).</p>
</caption>
<graphic xlink:href="fphar-12-744409-g007.tif"/>
</fig>
</sec>
<sec id="s3-6">
<title>No Detectable Estrogenic Compounds in the Decoction for Treating PMS</title>
<p>It was possible that the effective attenuation of the metabolomic state of PMS rats without significant change in the level of estrogen was through modulating the activity of estrogen receptors with interacting compounds in Zuogui-CSS. To address this possibility, the ligand-binding domain of estrogen receptor &#x3b1; (ER&#x3b1; LBD) was expressed and purified (<xref ref-type="sec" rid="s11">Supplementary Figure S21</xref>). STD, a ligand-based NMR technique (<xref ref-type="bibr" rid="B25">Mayer and Meyer, 2001</xref>), was employed to detect the possible interacting molecules in the decoction. The STD experiment involves subtracting a spectrum, in which the protein was selectively saturated with magnetic radiation, from another spectrum without the protein saturation. In the difference spectrum, only the signals of those compounds that received the magnetic radiation transferred from the protein will remain. Other compounds that do not bind to the protein will not receive the saturation transfer so their characteristic signal will not appear in the difference spectrum (<xref ref-type="bibr" rid="B26">Meyer and Peters, 2003</xref>). The techniques can detect K<sub>d</sub> values ranging between 10<sup>&#x2013;3</sup> and 10<sup>&#x2013;8</sup>&#xa0;M for the interacting compounds and is especially useful for detecting weak binders (<xref ref-type="bibr" rid="B25">Mayer and Meyer, 2001</xref>). Many phytoestrogens are with affinities in this range to estrogen receptors. For example, the K<sub>d</sub> value for daidzein binding ER&#x3b1; is 5.9 &#xd7; 10<sup>&#x2212;6</sup>&#xa0;M (<xref ref-type="bibr" rid="B36">van Lipzig et&#x20;al., 2004</xref>) and that for coumestrol is 1&#x20;&#xd7; 10<sup>&#x2212;4</sup>&#xa0;M (<xref ref-type="bibr" rid="B29">Qiu et&#x20;al., 2020</xref>). So the technique is applicable to detecting the like compounds in the decoctions if they are of reasonable concentration. The spectrum without the saturation transfer from the protein was obtained for Zuogui-CSS (<xref ref-type="fig" rid="F8">Figure&#x20;8A</xref>). In the STD difference spectrum (the upper spectrum in <xref ref-type="fig" rid="F8">Figure&#x20;8B</xref>), the only observed peaks were those from glycerol (3.54, 3.63, and 3.77&#xa0;ppm) and H<sub>2</sub>O (4.70&#xa0;ppm) in the solution (<xref ref-type="bibr" rid="B23">Lu et&#x20;al., 2018</xref>). These were nonspecific peaks due to their high concentrations as they also were present in the spectrum without the protein (lower spectrum in <xref ref-type="fig" rid="F8">Figure&#x20;8B</xref>). So, there was no detectable compound by STD in the decoction to interact with ER&#x3b1;.</p>
<fig id="F8" position="float">
<label>FIGURE 8</label>
<caption>
<p>STD NMR detection for estrogenic compounds in Zuogui-CSS. <bold>(A)</bold> The 1D <sup>1</sup>H NMR spectrum of Zuogui-CSS. <bold>(B)</bold> The STD spectra of Zuogui-CSS in the presence of ER&#x3b1;-LBD (upper red spectrum) and in the absence of ER&#x3b1;-LBD (lower blue spectrum). Only nonspecific solvent signals from glycerol (3.54, 3.63, and 3.77&#xa0;ppm) and H<sub>2</sub>O (4.70&#xa0;ppm) were observed in the STD spectra.</p>
</caption>
<graphic xlink:href="fphar-12-744409-g008.tif"/>
</fig>
<p>As these decoctions were through the stomach and intestinal tracts after the gavage, the gastrointestinal digestion could yield interacting compounds. To test this possibility, Zuogui-CSS was treated with SGF and SIF for the STD NMR experiments. The treatment with either SGF or SIF indeed produced new compounds (<xref ref-type="fig" rid="F9">Figure&#x20;9A</xref>). The decoction was also first treated with SGF and then with SIF simulating its passage through the gastrointestinal system. The resulting spectrum for the sequential treatment of Zuogui-CSS though was the superposition of spectra from Zuogui-CSS treated with SGF and SIF separately (<xref ref-type="fig" rid="F9">Figure&#x20;9A</xref>). These newly generated compounds by the gastrointestinal digestion were with no detectable interaction with ER&#x3b1; LBD either based on the STD NMR analyses (<xref ref-type="fig" rid="F9">Figures 9B&#x2013;D</xref>).</p>
<fig id="F9" position="float">
<label>FIGURE 9</label>
<caption>
<p>Gastrointestinal digestion of Zuogui-CSS produced no estrogenic compound. <bold>(A)</bold> <sup>1</sup>H NMR spectra of Zuogui-CSS treated with simulated gastrointestinal fluids. The blue-colored spectrum was for Zuogui-CSS without the treatment. The green-colored spectrum was for Zuogui-CSS treated with SIF for 4&#xa0;h. The red-colored spectrum was for Zuogui-CSS treated with SGF for 2&#xa0;h. The purple-colored spectrum was for Zuogui-CSS sequentially treated with SGF for 2&#xa0;h and SIF for 4&#xa0;h. Peaks for new compounds appeared after Zuogui-CSS was treated with either SGF, SIF, or both. <bold>(B)</bold> The STD spectra of Zuogui-CSS treated with SGF for 2&#xa0;h. The upper red-colored spectrum was from the sample with ER&#x3b1;-LBD and the lower blue-colored spectrum was from the sample without ER&#x3b1;-LBD. <bold>(C)</bold> The STD spectra of Zuogui-CSS treated with SIF for 4&#xa0;h. The upper red-colored spectrum was from the sample with ER&#x3b1;-LBD and the lower blue-colored spectrum was from the sample without ER&#x3b1;-LBD. <bold>(D)</bold> The spectra of Zuogui-CSS were treated sequentially with SGF for 2&#xa0;h and SIF for 4&#xa0;h. The upper red-colored spectrum was from the sample with ER&#x3b1;-LBD and the lower blue-colored spectrum was from the sample without ER&#x3b1;-LBD. The STD spectra were with only solvent signal peaks (e.g., glycerol, H<sub>2</sub>O, and self-degradation products of pepsin or pancreatin). There was no indication of any compound that could interact with ER&#x3b1;-LBD.</p>
</caption>
<graphic xlink:href="fphar-12-744409-g009.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>Perimenopause is a period of transition to menopause characterized by irregularity in the menstrual cycle with fluctuating and overall declining levels of estrogen in women. As the body conditions going through a significant transformation with the gradual cessation of reproductive functions, many perimenopausal women suffer from PMS. Hormone replacement therapy (HRT) is an established clinical practice for treating PMS (<xref ref-type="bibr" rid="B37">Whiteley et&#x20;al., 2013</xref>). However, serious side effects have also been reported for HRT (<xref ref-type="bibr" rid="B14">Hickey et&#x20;al., 2005</xref>; <xref ref-type="bibr" rid="B31">Sare et&#x20;al., 2008</xref>). For a transition to menopause, the declining level of estrogen and reproductive senescence is a natural process of aging. Supplementation of estrogenic compounds, such as that in HRT, could be countering a natural trend in the body. By directly compensating for the loss of estrogen, the PMS symptoms might be soothed but it could also be counterproductive and result in undesirable side effects. A better treatment strategy might be to palliate the symptoms of PMS without interfering with the body&#x2019;s natural transition to menopause such as supplementing estrogenic compounds.</p>
<p>The association of PMS with KD and LQS in TCM seems enigmatic and jargonistic to the general practitioners of medicine. However, the fact that the subsequent prescriptions based on the theory of TCM are effective is an indication that it is with sound rationales. Our data here indicated that Zuogui, Yougui, and CSS were efficacious to various degrees for treating PMS, with Zuogui-CSS adjusting body&#x2019;s conditions to a more seemingly desirable direction in a PMS model that was deemed to be with both KD and LQS. The best strategy, however, seemed to be treating both KD and LQS simultaneously with a combined decoction of Zuogui and CSS for the PMS rats. This combination treatment could bring the metabolomic state of PMS close to that of rats at a younger age before entering perimenopause. It was even more remarkable that this amelioration was done seemingly neither by directly upregulating the estrogen level nor by supplementing an estrogenic compound.</p>
<p>The dose of phytoestrogens for treating PMS is in the range of hundreds of milligrams to grams for humans (<xref ref-type="bibr" rid="B9">Crisafulli et&#x20;al., 2005</xref>; <xref ref-type="bibr" rid="B38">Xiao, 2008</xref>), which would be about milligrams to hundreds of milligrams for rats considering the difference in size and HED. Taking into accounts the volume of decoction feeding to the animal (4&#x2013;5&#xa0;ml) and the averaged molecular weight of phytoestrogens (&#x223c;250), the useful concentration for phytoestrogens should be around a few millimolars to hundreds of millimolars. Since the STD technique employed here is capable of detecting interacting compounds in the range of low millimolars to nanomolars, or even lower, the detection of no interacting compound in Zuogui-CSS by STD indicates that either there was just no such compound or the&#x20;amount of the compound was too small to effectively modulate the activity of estrogen receptors like those estrogenic compounds did in HRT. In light of the fact that the ingredients from two decoctions were to be mixed to yield the desirable results, it is possible that multiple factors are in play to attenuate the metabolomic state of the PMS&#x20;model.</p>
<p>The doses used for this study seem to be an important factor to obtain the results in this study as a previous study showed that the increased dosage of Zuogui at daily applications of either 13.78&#xa0;g/kg, 20.67&#xa0;g/kg, or 31&#xa0;g/kg for each rat, as compared to the daily dose of 3.04&#xa0;g/kg for each rat in this study, could lead to the increased serum level of estrogen in a dose-dependent manner (<xref ref-type="bibr" rid="B43">Zhao et&#x20;al., 2011</xref>). It implies that a well-calibrated and moderate dose of botanical drugs, Zuogui in this particular case, is important for ameliorating the disorder while avoiding the side effects as it is desirable to&#x20;treat PMS without elevating the level of estrogen to counter the natural trend of the body&#x2019;s transition to menopause.</p>
<p>The consistency between the metabolomic data in this study and the time-honored clinical practice of the abovementioned traditional Chinese prescriptions is an indication that the metabolomic indicators are applicable for assessing the efficacy of treating PMS with Chinese botanical drugs. It also implicates metabolomics as an invaluable tool to guide the use of traditional Chinese botanical drugs, in this case, by using a lower dose without elevating the level of serum estrogen for treating the disorder.</p>
<p>As effective as the treatment of the PMS model seems to be with the current prescription, the molecular mechanism of the treatment awaits further investigation. Does a ligand-independent ER pathway form the molecular basis of the TCM treatment of PMS? Or does the medicine applied here activate an ER-independent signaling pathway? In either case, the data presented here afford solid evidence for a better strategy to treat PMS with the traditional Chinese prescription of botanical&#x20;drugs.</p>
</sec>
</body>
<back>
<sec id="s5">
<title>Data Availability Statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="sec" rid="s11">Supplementary Material</xref>; further inquiries can be directed to the corresponding authors.</p>
</sec>
<sec id="s6">
<title>Ethics Statement</title>
<p>The animal study was reviewed and approved by the Animal Care and Use Committee of the Fujian University of Traditional Chinese Medicine (permission number: SYXK (Min) 2014-0005).</p>
</sec>
<sec id="s7">
<title>Author Contributions</title>
<p>JL, XC, and CW performed the experiments and analyzed the data. ZZ, LH, LR, PZ, XY, CL, and SL were involved in maintaining the animals, generating the models, and collecting the samples. CY, SW, YD, and HR participated in the production of the recombinant proteins and the NMR experiments. W&#x2019;nL, JS, HH, BG, and HY provided professional advice and helped in guiding the experiments. TL, XC, and CL designed and supervised the study and wrote the manuscript. All authors reviewed and approved the final version of the manuscript.</p>
</sec>
<sec id="s8">
<title>Funding</title>
<p>This study was supported by grants from the National Natural Science Foundation of China (81673882, 81774209, 31670729, and 31370724), Project 111 sponsored by the State Bureau of Foreign Experts and Ministry of Education of China (B2018017), Fujian Joint Research Grant for Health and Education (2019-WJ-39), and Fujian Grant for Research of Traditional Chinese Medicine (2017FJZYLC406).</p>
</sec>
<sec sec-type="COI-statement" id="s9">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s10">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s11">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2021.744409/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fphar.2021.744409/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="DataSheet1.PDF" id="SM1" mimetype="application/PDF" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<sec id="s12">
<title>Abbreviations</title>
<p>CSS, Chaihu-Shugan-San; ELISA, enzyme-linked immunosorbent assay; 1H NMR, proton nuclear magnetic resonance; HRT, hormone replacement therapy; KD, kidney deficiency; LQS, liver qi stagnation; OPLS-DA, orthogonal partial least-squares-discriminant analysis; PMS, perimenopausal syndrome; SPF, specific pathogen free; STD, saturation transfer difference; TCM, traditional Chinese medicine; VIP, variable influence on projection.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bruning</surname>
<given-names>J.&#x20;B.</given-names>
</name>
<name>
<surname>Parent</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Gil</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nowak</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pace</surname>
<given-names>M. C.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>Coupling of Receptor Conformation and Ligand Orientation Determine Graded Activity</article-title>. <source>Nat. Chem. Biol.</source> <volume>6</volume> (<issue>11</issue>), <fpage>837</fpage>&#x2013;<lpage>843</lpage>. <pub-id pub-id-type="doi">10.1038/nchembio.451</pub-id> </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cai</surname>
<given-names>H. B.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>G. L.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>C. H.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Z. S.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y. B.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Effect of Zhuang Jing Decoction on Learning and Memory Ability in Aging Rats</article-title>. <source>Rejuvenation Res.</source> <volume>19</volume> (<issue>4</issue>), <fpage>303</fpage>&#x2013;<lpage>308</lpage>. <pub-id pub-id-type="doi">10.1089/rej.2015.1751</pub-id> </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cai</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Progress of Research on Female Animal Models of Perimenopause</article-title>. <source>Chin. J.&#x20;Exp. Tradit. Med. Formulae</source> (<issue>10</issue>), <fpage>71</fpage>&#x2013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.13422/j.cnki.syfjx.2007.10.022</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Weljie</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Newton</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Leveraging Latent Information in NMR Spectra for Robust Predictive Models</article-title>. <source>Pac. Symp. Biocomput.</source>, <fpage>115</fpage>&#x2013;<lpage>126</lpage>. </citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Integrated Systems Pharmacology, Urinary Metabonomics, and Quantitative Real-Time PCR Analysis to Uncover Targets and Metabolic Pathways of the You-Gui Pill in Treating Kidney-Yang Deficiency Syndrome</article-title>. <source>Int. J.&#x20;Mol. Sci.</source> <volume>20</volume> (<issue>15</issue>). <pub-id pub-id-type="doi">10.3390/ijms20153655</pub-id> </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Effects of Herbal Formula Chaihu Shugan San on the Expression of Genes in cAMP/Ca<sup>2&#x2b;</sup> Signal Pathway in hippocampus of Perimenopausal Rats with Liver-Qi Stagnation Syndrome</article-title>. <source>China J.&#x20;Tradit. Chin. Med. Pharm.</source> <volume>29</volume> (<issue>05</issue>), <fpage>1464</fpage>&#x2013;<lpage>1469</lpage>. <comment>CNKI:SUN:BXYY.0.2014-05-038</comment>. </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhuo</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>The Metabolomic Rationale for Treating Perimenopausal Syndrome as Kidney Deficiency</article-title>. <source>Evid. Based Complement. Alternat. Med.</source> <volume>2020</volume>, <fpage>8568353</fpage>. <pub-id pub-id-type="doi">10.1155/2020/8568353</pub-id> </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chong</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Soufan</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Caraus</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bourque</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>MetaboAnalyst 4.0: towards More Transparent and Integrative Metabolomics Analysis</article-title>. <source>Nucleic Acids Res.</source> <volume>46</volume> (<issue>W1</issue>), <fpage>W486</fpage>&#x2013;<lpage>W494</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gky310</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crisafulli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Altavilla</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Marini</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Bitto</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cucinotta</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Frisina</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2005</year>). <article-title>Effects of the Phytoestrogen Genistein on Cardiovascular Risk Factors in Postmenopausal Women</article-title>. <source>Menopause</source> <volume>12</volume> (<issue>2</issue>), <fpage>186</fpage>&#x2013;<lpage>192</lpage>. <pub-id pub-id-type="doi">10.1097/00042192-200512020-00013</pub-id> </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elkins</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Marcus</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Stearns</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Perfect</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rajab</surname>
<given-names>M. H.</given-names>
</name>
<name>
<surname>Ruud</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2008</year>). <article-title>Randomized Trial of a Hypnosis Intervention for Treatment of Hot Flashes Among Breast Cancer Survivors</article-title>. <source>J.&#x20;Clin. Oncol.</source> <volume>26</volume> (<issue>31</issue>), <fpage>5022</fpage>&#x2013;<lpage>5026</lpage>. <pub-id pub-id-type="doi">10.1200/jco.2008.16.6389</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Effect of Zuoguiwan on Neuro-Endocrine-Immune Function of Kidney-Yin Deficiency Rats</article-title>. <source>Chin. J.&#x20;Exp. Tradit. Med. Formulae</source> <volume>23</volume> (<issue>22</issue>), <fpage>155</fpage>&#x2013;<lpage>159</lpage>. <pub-id pub-id-type="doi">10.13422/j.cnki.syfjx.2017220155</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gemmell</surname>
<given-names>L. C.</given-names>
</name>
<name>
<surname>Webster</surname>
<given-names>K. E.</given-names>
</name>
<name>
<surname>Kirtley</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Vincent</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Zondervan</surname>
<given-names>K. T.</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>C. M.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>The Management of Menopause in Women with a History of Endometriosis: a Systematic Review</article-title>. <source>Hum. Reprod. Update</source> <volume>23</volume> (<issue>4</issue>), <fpage>481</fpage>&#x2013;<lpage>500</lpage>. <pub-id pub-id-type="doi">10.1093/humupd/dmx011</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>X. H.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>H. J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y. D.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>W. X.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Z. G.</given-names>
</name>
<name>
<surname>Wilkinson</surname>
<given-names>C. E.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Small Fatigue Crack Propagation in Al-Cu alloy Laminated Structure via Ultrasonic Consolidation</article-title>. <source>J.&#x20;Traditi. Chin. Med.</source> <volume>55</volume> (<issue>01</issue>), <fpage>83</fpage>&#x2013;<lpage>87</lpage>. <pub-id pub-id-type="doi">10.13288/j.11-2166/r.2014.01.022</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hickey</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>S. R.</given-names>
</name>
<name>
<surname>Sturdee</surname>
<given-names>D. W.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Treatment of Menopausal Symptoms: what Shall We Do Now</article-title>. <source>Lancet</source> <volume>366</volume> (<issue>9483</issue>), <fpage>409</fpage>&#x2013;<lpage>421</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(05)66519-1</pub-id> </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kraeuter</surname>
<given-names>A. K.</given-names>
</name>
<name>
<surname>Guest</surname>
<given-names>P. C.</given-names>
</name>
<name>
<surname>Sarnyai</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>The Open Field Test for Measuring Locomotor Activity and Anxiety-like Behavior</article-title>. <source>Methods Mol. Biol.</source> <volume>1916</volume>, <fpage>99</fpage>&#x2013;<lpage>103</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4939-8994-2_9</pub-id> </citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Jujube Promotes Learning and Memory in a Rat Model by Increasing Estrogen Levels in the Blood and Nitric Oxide and Acetylcholine Levels in the Brain</article-title>. <source>Exp. Ther. Med.</source> <volume>5</volume> (<issue>6</issue>), <fpage>1755</fpage>&#x2013;<lpage>1759</lpage>. <pub-id pub-id-type="doi">10.3892/etm.2013.1063</pub-id> </citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Effects of Chaihu Shugan Powder on the ERK1/2 Expression of hippocampus in the Rat Model of Perimenopausal Syndrome with Liver Stagnation Syndrome</article-title>. <source>China J.&#x20;Tradit. Chin. Med. Pharm.</source> <volume>29</volume> (<issue>10</issue>), <fpage>3201</fpage>&#x2013;<lpage>3204</lpage>. <comment>CNKI:SUN:BXYY.0.2014-10-053</comment>. </citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Effect of Chaihushugan San on Expression of the Raf/mitogen-Activated Protein Kinase/extracellular Signal-Regulated Kinase Pathway in the Hippocampi of Perimenopausal Rats Induced by Immobilization Stress</article-title>. <source>J.&#x20;Traditi. Chin. Med.</source> <volume>35</volume> (<issue>4</issue>), <fpage>445</fpage>&#x2013;<lpage>452</lpage>. <pub-id pub-id-type="doi">10.1016/s0254-6272(15)30123-0</pub-id> </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Administration of Lactobacillus Helveticus NS8 Improves Behavioral, Cognitive, and Biochemical Aberrations Caused by Chronic Restraint Stress</article-title>. <source>Neuroscience</source> <volume>310</volume>, <fpage>561</fpage>&#x2013;<lpage>577</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2015.09.033</pub-id> </citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Interrelationship Study of Liver Depression and Estrogen in Perimenopausal Syndrome</article-title>. <source>China J.&#x20;Tradit. Chin. Med. Pharm.</source> <volume>26</volume> (<issue>09</issue>), <fpage>1961</fpage>&#x2013;<lpage>1963</lpage>. <comment>CNKI:SUN:BXYY.0.2011-09-018</comment>. </citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Clinical Research on Rules of TCM Syndrome Elements of Perimenopausal Syndrome</article-title>. <source>J.&#x20;Fujian Univ. Tradit. Chin. Med.</source> <volume>19</volume> (<issue>06</issue>), <fpage>3</fpage>&#x2013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.13261/j.cnki.jfutcm.002247</pub-id> </citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Clinic Research of Treating Perimenopausal Syndrome Tongue Demonstration Changes by Chaihu Shugan Decoction</article-title>. <source>China J.&#x20;Tradit. Chin. Med. Pharm.</source> <volume>25</volume> (<issue>02</issue>), <fpage>201</fpage>&#x2013;<lpage>203</lpage>. <comment>CNKI:SUN:BXYY.0.2010-02-013</comment>. </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Validated &#xb9;H and 13C Nuclear Magnetic Resonance Methods for the Quantitative Determination of Glycerol in Drug Injections</article-title>. <source>Molecules</source> <volume>23</volume> (<issue>5</issue>). <pub-id pub-id-type="doi">10.3390/molecules23051177</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marques-Lopes</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tesfaye</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Israilov</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Van Kempen</surname>
<given-names>T. A.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Glass</surname>
<given-names>M. J.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Redistribution of NMDA Receptors in Estrogen-Receptor-&#x3b2;-Containing Paraventricular Hypothalamic Neurons Following Slow-Pressor Angiotensin II Hypertension in Female Mice with Accelerated Ovarian Failure</article-title>. <source>Neuroendocrinology</source> <volume>104</volume> (<issue>3</issue>), <fpage>239</fpage>&#x2013;<lpage>256</lpage>. <pub-id pub-id-type="doi">10.1159/000446073</pub-id> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mayer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Group Epitope Mapping by Saturation Transfer Difference NMR to Identify Segments of a Ligand in Direct Contact with a Protein Receptor</article-title>. <source>J.&#x20;Am. Chem. Soc.</source> <volume>123</volume> (<issue>25</issue>), <fpage>6108</fpage>&#x2013;<lpage>6117</lpage>. <pub-id pub-id-type="doi">10.1021/ja0100120</pub-id> </citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meyer</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>NMR Spectroscopy Techniques for Screening and Identifying Ligand Binding to Protein Receptors</article-title>. <source>Angew. Chem. Int. Ed. Engl.</source> <volume>42</volume> (<issue>8</issue>), <fpage>864</fpage>&#x2013;<lpage>890</lpage>. <pub-id pub-id-type="doi">10.1002/anie.200390233</pub-id> </citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miao</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Xin</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Standard (Draft) for Preparation of Perimenopausal Syndrome Model</article-title>. <source>China J.&#x20;Tradit. Chin. Med. Pharm.</source> <volume>33</volume> (<issue>03</issue>), <fpage>996</fpage>&#x2013;<lpage>1000</lpage>. <comment>CNKI:SUN:BXYY.0.2018-03-051</comment>. </citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nelson</surname>
<given-names>H. D.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Menopause</article-title>. <source>The Lancet</source> <volume>371</volume> (<issue>9614</issue>), <fpage>760</fpage>&#x2013;<lpage>770</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(08)60346-3</pub-id> </citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qiu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Luan</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Binding Specificities of Estrogen Receptor with Perfluorinated Compounds: A Cross Species Comparison</article-title>. <source>Environ. Int.</source> <volume>134</volume>, <fpage>105284</fpage>. <pub-id pub-id-type="doi">10.1016/j.envint.2019.105284</pub-id> </citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reagan-Shaw</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nihal</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ahmad</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Dose Translation from Animal to Human Studies Revisited</article-title>. <source>FASEB J.</source> <volume>22</volume> (<issue>3</issue>), <fpage>659</fpage>&#x2013;<lpage>661</lpage>. <pub-id pub-id-type="doi">10.1096/fj.07-9574LSF</pub-id> </citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sare</surname>
<given-names>G. M.</given-names>
</name>
<name>
<surname>Gray</surname>
<given-names>L. J.</given-names>
</name>
<name>
<surname>Bath</surname>
<given-names>P. M.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Association between Hormone Replacement Therapy and Subsequent Arterial and Venous Vascular Events: a Meta-Analysis</article-title>. <source>Eur. Heart J.</source> <volume>29</volume> (<issue>16</issue>), <fpage>2031</fpage>&#x2013;<lpage>2041</lpage>. <pub-id pub-id-type="doi">10.1093/eurheartj/ehn299</pub-id> </citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stearns</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Ullmer</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>L&#xf3;pez</surname>
<given-names>J.&#x20;F.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Isaacs</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Hayes</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Hot Flushes</article-title>. <source>Lancet</source> <volume>360</volume> (<issue>9348</issue>), <fpage>1851</fpage>&#x2013;<lpage>1861</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(02)11774-0</pub-id> </citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Strekalova</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Spanagel</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bartsch</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Henn</surname>
<given-names>F. A.</given-names>
</name>
<name>
<surname>Gass</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Stress-induced Anhedonia in Mice Is Associated with Deficits in Forced Swimming and Exploration</article-title>. <source>Neuropsychopharmacology</source> <volume>29</volume> (<issue>11</issue>), <fpage>2007</fpage>&#x2013;<lpage>2017</lpage>. <pub-id pub-id-type="doi">10.1038/sj.npp.1300532</pub-id> </citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Su</surname>
<given-names>Z. H.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>H. M.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H. W.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>Y. F.</given-names>
</name>
<name>
<surname>An</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>Z. M.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Hippocampus and Serum Metabolomic Studies to Explore the Regulation of Chaihu-Shu-Gan-San on Metabolic Network Disturbances of Rats Exposed to Chronic Variable Stress</article-title>. <source>Mol. Biosyst.</source> <volume>10</volume> (<issue>3</issue>), <fpage>549</fpage>&#x2013;<lpage>561</lpage>. <pub-id pub-id-type="doi">10.1039/c3mb70377k</pub-id> </citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Su</surname>
<given-names>Z. H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S. Q.</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>G. A.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>C. Y.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Y. G.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H. W.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Urinary Metabonomics Study of Anti-depressive Effect of Chaihu-Shu-Gan-San on an Experimental Model of Depression Induced by Chronic Variable Stress in Rats</article-title>. <source>J.&#x20;Pharm. Biomed. Anal.</source> <volume>55</volume> (<issue>3</issue>), <fpage>533</fpage>&#x2013;<lpage>539</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpba.2011.02.013</pub-id> </citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Lipzig</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>ter Laak</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Jongejan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Vermeulen</surname>
<given-names>N. P.</given-names>
</name>
<name>
<surname>Wamelink</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Geerke</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2004</year>). <article-title>Prediction of Ligand Binding Affinity and Orientation of Xenoestrogens to the Estrogen Receptor by Molecular Dynamics Simulations and the Linear Interaction Energy Method</article-title>. <source>J.&#x20;Med. Chem.</source> <volume>47</volume> (<issue>4</issue>), <fpage>1018</fpage>&#x2013;<lpage>1030</lpage>. <pub-id pub-id-type="doi">10.1021/jm0309607</pub-id> </citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Whiteley</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>DiBonaventura</surname>
<given-names>Md.</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>J.&#x20;S.</given-names>
</name>
<name>
<surname>Alvir</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>The Impact of Menopausal Symptoms on Quality of Life, Productivity, and Economic Outcomes</article-title>. <source>J.&#x20;Womens Health (Larchmt)</source> <volume>22</volume> (<issue>11</issue>), <fpage>983</fpage>&#x2013;<lpage>990</lpage>. <pub-id pub-id-type="doi">10.1089/jwh.2012.3719</pub-id> </citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiao</surname>
<given-names>C. W.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Health Effects of Soy Protein and Isoflavones in Humans</article-title>. <source>J.&#x20;Nutr.</source> <volume>138</volume> (<issue>6</issue>), <fpage>1244S</fpage>&#x2013;<lpage>9S</lpage>. <pub-id pub-id-type="doi">10.1093/jn/138.6.1244S</pub-id> </citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>H. W.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Kuang</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Effectiveness and Safety of Warm Needle Acupuncture on Insomnia in Climacteric Women: Protocol for a Systematic Review and Meta-Analysis</article-title>. <source>Medicine (Baltimore)</source> <volume>98</volume> (<issue>20</issue>), <fpage>e15637</fpage>. <pub-id pub-id-type="doi">10.1097/MD.0000000000015637</pub-id> </citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Correlative Study on Monoamine Neurotransmitters and Stagnation of Liver Qi Syndrome and Mix Syndrome of Perimenopausal Period Syndrome</article-title>. <source>China J.&#x20;Tradit. Chin. Med. Pharm.</source> <volume>33</volume> (<issue>01</issue>), <fpage>58</fpage>&#x2013;<lpage>61</lpage>. <comment>CNKI:SUN:BXYY.0.2018-01-015</comment>. </citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeng</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>2-Phenylacetamide Isolated from the Seeds of Lepidium Apetalum and its Estrogen-like Effects <italic>In Vitro</italic> and <italic>In Vivo</italic>
</article-title>. <source>Molecules</source> <volume>23</volume> (<issue>9</issue>). <pub-id pub-id-type="doi">10.3390/molecules23092293</pub-id> </citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Q. G.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tu</surname>
<given-names>J.&#x20;Y.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Hypersensitivity of the Hippocampal CA3 Region to Stress-Induced Neurodegeneration and Amyloidogenesis in a Rat Model of Surgical Menopause</article-title>. <source>Brain</source> <volume>136</volume>, <fpage>1432</fpage>&#x2013;<lpage>1445</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awt046</pub-id> </citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>H. X.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>H. L.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>S. X.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Ni</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Action Mechanism of Zuo Gui Yin Decoction&#x27;s Promotion on Estradiol Production in Rats during the Peri-Menopausal Period</article-title>. <source>J.&#x20;Ethnopharmacol.</source> <volume>134</volume> (<issue>1</issue>), <fpage>122</fpage>&#x2013;<lpage>129</lpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2010.11.073</pub-id> </citation>
</ref>
</ref-list>
</back>
</article>